Adequacy of family history taking in ovarian cancer patients: a population-based study

[1]  L. Strong,et al.  Clinically relevant changes in family history of cancer over time. , 2011, Journal of the American Medical Association (JAMA).

[2]  J. Gohagan,et al.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.

[3]  Barry Rosen,et al.  Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.

[4]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[5]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[6]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[7]  Muin J. Khoury,et al.  Family history in public health practice: a genomic tool for disease prevention and health promotion. , 2010, Annual review of public health.

[8]  L. Vatten,et al.  Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population‐based study , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[9]  J. Young,et al.  Family history? The forgotten question in high‐risk colorectal cancer patients , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[10]  S. Gayther,et al.  The Contribution of BRCA1 and BRCA2 to Ovarian Cancer , 2009, Molecular oncology.

[11]  A. Godwin,et al.  Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management , 2009, Molecular oncology.

[12]  E. Woodward,et al.  Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high‐risk and population risk women is ineffective , 2007, BJOG : an international journal of obstetrics and gynaecology.

[13]  P. Krijnen,et al.  Family history is neglected in the work-up of patients with colorectal cancer: a quality assessment using cancer registry data , 2007, Familial Cancer.

[14]  F. Couch,et al.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. , 2006, JAMA.

[15]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[16]  R. Calderon-Margalit,et al.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature , 2004, International journal of cancer.

[17]  H. Murff,et al.  Cancer risk assessment: quality and impact of the family history interview. , 2004, American journal of preventive medicine.

[18]  H. Murff,et al.  Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. , 2004, JAMA.

[19]  Å. Borg,et al.  One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. , 2004, European journal of cancer.

[20]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[21]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[22]  Argyrios Ziogas,et al.  Validation of family history data in cancer family registries. , 2003, American journal of preventive medicine.

[23]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[24]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[25]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[26]  D. Evans,et al.  The accuracy of diagnoses as reported in families with cancer: a retrospective study , 1999, Journal of medical genetics.

[27]  D. Easton,et al.  A systematic review and meta‐analysis of family history and risk of ovarian cancer , 1998, British journal of obstetrics and gynaecology.

[28]  T. Rebbeck,et al.  BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. , 1998, American journal of obstetrics and gynecology.